- Moderna stock slides again as investors lose faith.
- MRNA shares also suffering as UK fully opens up and Biden says normal is on the way.
- Moderna lacks alternative revenue streams.
FXStreet had turned bearish on this stock after resutls in November, but the emergence of the Omicron variant did change things somewhat. Moderna (MRNA) shares spiked as panic gripped markets and Omicron was an unknown entity.
The shares quickly spiked to nearly $380 from a post-earnings low of $220. However, Moderna put in a bearish shooting star candle that signified impending losses. The news was finally confirmed in our view when on December 20 Moderna said its jab was effective against Omicron. Moderna shares spiked intraday but actually closed 6% lower as investors ditched the name.
The reason as we now apparently know is that it appears Omicron is much less serious that other variants. More transmissable, yes, but the variant results in much fewer hospitalizations. Experts have now come to the conclusion that this is the end game for covid. This will be the final covid winter. This appears to have gotten confirmtaion from the UK yesterday as emabttled Prime Minister Johnson gets to luckily deflect attention away from him by announcing an end to restrictions. In the US President Biden says things are nearly back to normal. Europe is a little further behind, but already some countries such as Ireland are significantly easing restrictions.
Moderna Stock News
Moderna cracked below key support at $188 when it lost nearly 7% yesterday. Markets are not in a charitable mood, and increased attention is now being focused on potential short names and dumping high growth stocks. FXStreet has identified before the one-trick pony that MRNA potentially is. It is hugely reliant on covid vaccines for revenue. It does have some other products in the pipeline as shown below, but none are yet commercial.
Source: Moderna www.modernatx.com/pipeline
Moderna Stock Forecast
$188.40 was a big level going back to February of last year. The stock eventually broke above in summer 2021 and staged a successful pullback test before marching higher. Now that it is broken, the next target is $157.70 and then some decent volume support at $147. Resistance at $211 is the short-term pivot.
Moderna (MRNA) chart, daily
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD consolidates as traders keenly await Australian employment details
AUD/USD oscillates in a range just above a nearly two-week low touched on Tuesday as traders opt to wait on the sidelines ahead of the Australian employment figures. A weaker US Dollar, which remains depressed near a four-month low amid Fed rate cut bets, lends support to the currency pair.
EUR/USD crosses over 1.0900 on Wednesday as Euro bulls gear up for ECB rate call
EUR/USD rallied into fresh 18-week highs on Wednesday as market sentiment tilts firmly into the risk-on side ahead of the European Central Bank’s latest rate call slated for Thursday. Broad-market risk appetite remains pinned into the ceiling as markets fully price in a rate cut from the Federal Reserve on September 18.
Gold price remains close to record high amid Fed rate cut expectations
Gold price oscillates in a range during the Asian session on Thursday and seems to have stalled a modest retracement slide from a fresh record high touched the previous day. The prevalent risk-on environment acts as a headwind for the XAU/USD. The near-near bias, however, remains tilted in favor of bulls.
Ethereum ETF issuers file updated drafts, ETH staking still a possibility
Ethereum is down 1% on Wednesday as issuers began filing their final spot ETH ETF S-1 drafts with the SEC in anticipation of a launch on July 23. Meanwhile, SEC commissioner Hester Peirce also said the regulator may reconsider its position on ETH staking within the ETFs.
Australian Unemployment Rate seen steady at 4% in June
With sentiment dominating financial markets, the Australian Bureau of Statistics will release the monthly employment report on Thursday at 1:30 GMT. The country is expected to have added 20K new positions in June, while the Unemployment Rate is foreseen to remain steady at 4%.